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Abstract
Background Muscle wasting can be accelerated by chronic diseases such as heart failure and is one of the major causes of
disability, morbidity, and mortality in this population. We aimed to investigate the incidence of muscle wasting and its
associated factors in dilated cardiomyopathy patients younger than 55 years of age.
Methods Between April 2014 and December 2015, all symptomatic patients with a diagnosis of non-ischaemic dilated
cardiomyopathy who were referred to heart failure clinic were included in our study.
Dual energy X-ray absorptiometry was used to evaluate body composition and identify muscle wasting. Muscle mass was
calculated as the ratio of an individual’s total lean mass of legs and arms (also called appendicular skeletal muscle) to their
squared height (kg/m2). The muscle mass values of less than 5.45 kg/m2 for women and 7.26 kg/m2 for men were considered
low.
Results A total of 55 patients (32 male) were included. The mean (standard deviation) of age was 37.3 (10.1) years, and the
mean of left ventricular ejection fraction was 21.4%. Most of the patients were in the New York Heart Association classes of II
and II–III. Twenty-six patients (47.3%) met criteria for muscle wasting. Patients with muscle wasting had lower left ventricular
ejection fraction, lower 6-min walk distance, and higher New York Heart Association function class and hospitalization rate.
Conclusions We concluded that muscle wasting might be present in younger patients with heart failure, particularly in those
who are in worse clinical condition.
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Introduction
Muscle wasting and impaired skeletal muscle function in
elderly should not be underestimated in heart failure.1,2 The
adaptive changes in musculoskeletal system following the
occurrence of heart failure play key roles in the development
of many symptoms related to heart failure syndrome includ-
ing exercise intolerance and fatigue.1–5 Although muscle
wasting was first introduced as a phenomenon secondary to
ageing, it is more prevalent in patients with a chronic illness
such as heart failure, chronic renal failure, and chronic lung
disease.1,6–8 In most studies regarding muscle wasting in
heart failure, elderly patients have been selected.2–5,9 The
results of these studies indicate a higher prevalence of
muscle wasting in older patients with heart failure compared
with healthy subjects who are at the same age.2–5,9 There are
only scant data regarding the presence of muscle wasting in
younger patients with heart failure,3 and it is not known
whether heart failure could possibly be a risk factor for
muscle wasting regardless of ageing process or not.
In the current study, we sought to investigate the
incidence of muscle wasting and its associated factors in
younger patients with idiopathic dilated cardiomyopathy
(DCM) who were referred to our centre.
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Methods
Patient selection
Between April 2014 and December 2015, among patients
referred to the outpatient heart failure clinic of Rajaie
Cardiovascular, Medical and Research Center, a tertiary
centre for cardiovascular diseases in Iran, 55 patients were
consecutively enrolled according to the following
inclusion/exclusion criteria.
The inclusion criteria comprised idiopathic, non-ischaemic
DCM with a left ventricular ejection fraction (LVEF) ≤40%,
age under 55 years, a New York Heart Association (NYHA)
class of I to III, and participant willingness to be enrolled into
the study. All study participants had to be on guideline-
directed medical therapy for at least 3 months.
The patients with NYHA class IV and those with severe
oedema and ascites, history of any other chronic diseases
including any degrees of renal dysfunction (with or without
history of haemodialysis), connective tissue diseases, chronic
obstructive pulmonary disease, skeletal myopathies, endo-
crine disorders (diabetes mellitus and thyroid disorders),
chronic gastrointestinal diseases, malignancies as well as
patients with history of cachexia (more than 5% weight loss
over the last 6 months) were excluded.
The study was approved by research and ethic committee
of Rajaie Cardiovascular, Medical and Research Center, and
written informed consent was obtained from all patients.
A thorough clinical history was obtained and a detailed
physical examination was performed for all patients. The
presence of fatigue, dizziness, and loss of appetite were
asked and recorded. The NYHA function class was assessed
considering the severity of the limitations in ordinary physical
activities, where class I indicates no symptom, class II
indicates presence of symptoms in ordinary activities, class
III indicates symptoms at less than ordinary activities, and
finally, class IV indicates symptoms of dyspnoea at rest.10
The body mass index (BMI) was calculated by dividing the
weight to square of height.
The patients were also asked for their hospitalization
history during the last 6 months, and any history of hospital-
ization due to any cardiovascular causes including decompen-
sated heart failure was recorded.
The functional capacity and exercise tolerance of patients
were assessed by a 6-min walk test (6MWT) according to
the standard protocol.11
Laboratory tests
All blood was collected from all patients after 12–14 h over-
night fasting. The laboratory tests including complete blood
count, haemoglobin level, lipid profile (triglyceride, total
cholesterol, low density lipoprotein, and high density
lipoprotein), blood urea nitrogen, creatinine, serum albumin,
serum total protein, N-terminal brain natriuretic peptide (pro
BNP), and 25 hydroxy vitamin D3 were performed at our
laboratory on the day of blood collection.
Evaluation of skeletal muscle mass
Dual energy X-ray absorptiometry (DXA) was used to evaluate
body composition and muscle mass as well.
Dual energy X-ray absorptiometry scanning
The DXA scans were performed by a Hologic Discovery Wi
DXA system (Hologic Inc. Bedford, MA, USA, 2011), using
the fan beam with perpendicular orientation to the longitudi-
nal axis of the body. Participants received one whole-body
scan using the manufacturer’s standard scan and positioning
protocols. Spine phantom quality control scans were ac-
quired in advance for all studies.
Scan analysis
Using the region of interest placement recommended by the
manufacturer, all of the images were analysed using
the Hologic Apex 3.3 and Auto Whole Body 13.3 software.
The analysis resulted in total, subtotal (headless), and stan-
dard sub-regional (right and left arms, right and left legs,
and trunk) measures of the following parameters: bone
mineral content in grammes (g), projected bone area (Area)
in cm2, bone mineral density (bone mineral density = bone
mineral content/Area) in g/cm2, fat mass in grammes and
lean mass in grammes as well as per cent fat. Total body
%Fat, fat mass/height ratio (kg/m2), Android/Gynoid ratio,
%Fat trunk/%Fat legs, and trunk/limb fat mass ratio were also
derived from these standard regions.
Identifying the muscle wasting
According to previous studies,12,13 relative skeletal muscle
mass was considered to define muscle wasting. The relative
skeletal muscle mass was calculated by dividing the appen-
dicular skeletal muscle mass to the square of height. The
values less than 7.26 kg/m2 in men and 5.45 kg/m2 in women
were considered as muscle wasting.12,13
Statistical analysis
IBM SPSS statistics 19 for Windows (IBM Corp, Armonk, NY,
USA) was used for all statistical analyses. One sample
Kolmogorov Smirnov test was used to assess the normal
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distribution of variables. Categorical variables were
expressed as number (percentage), and quantitative variables
were expressed as mean (standard deviation) or median
(interquartile range) as appropriate. Student’s t-test, chi-
squared, and Mann–Whitney tests were used for compari-
sons and associations, as appropriate. Multivariate analysis
was performed using binary logistic regression to assess the
independent predictor for muscle wasting. P values <0.05
were considered significant.
Results
A total of 55 patients (32 males) with DCM were included in
this study. The mean (standard deviation) of age was 37.3
(10.1) years. The mean LVEF was 21.4% and most of the pa-
tients (50.9%) were in NYHA class II or II–III. Table 1 depicts
demographic and clinical characteristics of study population.
Table 2 shows patients’ medications.
Assessment of skeletal muscle mass by DXA scanning
showed that 26 patients (47.3%) met criteria for muscle
wasting. The comparison of baseline, clinical, and laboratory
characteristics of patients with and without muscle wasting
is summarized in Tables 3 and 4.
There was no difference between two groups in terms of
age. Muscle wasting was more prevalent in men (56% in
men vs. 34% in women), but this difference was not statisti-
cally significant (P = 0.1).
In this study, patients with muscle wasting had significantly
lower BMI (22.4 vs. 26.1 kg/m2, P < 0.001), lower LVEF
(P = 0.01), and higher NYHA class (P = 0.01).
The study participants were askedwhether they have history
of fatigue, dizziness, and loss of appetite, and there was no sig-
nificant difference between the two groups with and without
muscle wasting. There was also no statistically significant differ-
ence between the two groups regarding their disease duration.
However, the patients with muscle wasting had a lower 6-min
walk distance (338 vs. 440 m, P = 0.003) and had been hospital-
ized more frequently over the last 3 months (P = 0.008).
Regarding patients’ medications (Table 2), all patients
were treated with angiotensin converting enzyme
inhibitors/angiotensin receptor blockers, beta blockers,
Spironolactone, and diuretics according to the guidelines.
However, only 11% were taking the maximum tolerated or
recommended optimum dose of the regimen. There was no
statistically meaningful difference between the two groups
regarding heart failure medical therapy (P = 0.8).
Laboratory findings
As shown in Table 4, although the serum level of N-terminal
pro BNP was higher in patients with muscle wasting, it was
not statistically significant. There were also no statistically sig-
nificant differences between the two groups regarding the
measures of lipid profile, serum albumin, and protein level
or vitamin D3 level.
The bone density was also evaluated in this study. None of
our study participants had osteoporosis in DXA examination,
and as it was expected, the presence of osteopenia was ac-
companied with salient lower Vitamin D3 level (12.4 ± 4.4
to 23.9 ± 18.9, P value 0.002).
Multivariate analysis
A logistic regression model with backward elimination
method was applied to assess the adjusted associations
Table 1 Demographic and clinical characteristic of study population
(n = 55)
Characteristics Value
Gender (n, %)
Female 23 (42)
Male 32 (58)
Age, year, mean (SD) 37.3 (10.1)
BMI, kg/m2, mean (SD) 24.3 (3.7)
NYHA class (n, %)
I, I–II 20 (36.4)
II, II–III 28 (50.9)
III 7 (12.7)
GDMT, number (%) 55 (100)
GDMT at maximum recommended dose, number
(%)
10 (18.2)
LVEF, %, mean (SD) 21.4 (9.4)
Creatinine (mg/dL), mean (SD) 0.8 (0.2)
6MWT (metre), mean (SD) 395.9 (139.8)
Pro BNP (ng/dL), median (IQR) 835 (132–1700)
Haemoglobin (g/L), mean (SD) 13.9 (2)
Serum albumin (g/L) 42.9 (5)
Serum total protein (g/L) 69.8 (6.4)
Sodium (mmol/L) 137.3 (4.2)
Potassium (mmol/L) 4.2 (0.4)
Triglyceride (mg/dL) 156.6 (86)
Cholesterol (mg/dL) 177.9(54.7)
HDL (mg/dL) 40.6 (11.2)
LDL (mg/dL) 102.5 (35.4)
6MWT, 6-min walk test; BMI, body mass index; BNP, brain natri-
uretic peptide; GDMT, guideline-directed medical therapy; HDL,
high density lipoprotein; IQR, interquartile range; LDL, low density
lipoprotein; LVEF, left ventricular ejection fraction; NYHA, New
York Heart Association; SD, standard deviation.
Table 2 Medications and devices of study population (n = 55)
Medication Number(%)
ACEI/ARB 55(100)
Beta blocker 55(100)
MRA 55(100)
Diuretics 55(100)
Hydralazine +Isosorbide dinitrate 11(20)
Digoxin 18(32.7)
Warfarin 12(21.8)
Amiodarone 7(12.7)
ICD/CRT 22
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin
receptor blockers; ICD, implantable cardiac defibrillator; CRT,
cardiac resynchronization therapy; MRA, Mineralocorticoid Recep-
tor Antagonists.
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between muscle wasting and other predictors which had
been detected in bi-variate analysis. It was found that among
the several variables including gender, NYHA class, BMI, pro
BNP, 6MWT, and LVEF only BMI had independent associa-
tions with the presence of muscle wasting. [Beta: 1.104,
P-value: 0.01, odds ratio (95% confidence interval): 0.331
(0.134–0.82)].
The multivariate analysis for the investigation of associa-
tion between muscle wasting and recent hospitalization after
adjustment of other predictors revealed muscle wasting
could not be an independent predictor for recent hospitaliza-
tion. The strongest predictor for recent hospitalization was
NYHA function class in this study. [Beta: 1.64, P-value: 0.01,
odds ratio (95% confidence interval): 5.1(1.4–18.3)].
Discussion
In this study, we found considerable numbers of DCM pa-
tients aged less than 55 years who showed evidence of mus-
cle wasting. The muscle wasting or sarcopenia, defined as
ageing-related muscle mass loss, is generally considered a
problem in people aged 60 years and above.6,12–15 The prev-
alence of muscle wasting and sarcopenia in healthy people
between 60 and 70 years has been reported between 5%
and 30% in different studies. This prevalence is increased in
elderly with a chronic disease such as heart failure. However,
there is no consensus with regard to the precise age range for
this syndrome.1–3,6,9,12–16
After the first definition of sarcopenia by Irwin Rosenberg,
many investigators have studied different aspects of this phe-
nomenon in different subgroups of population including
healthy persons and patients suffering from chronic illnesses
like chronic heart failure or renal failure.4,6,7,12–14,17
Akiyama et al. presented a prevalence of 20% for muscle
wasting in patients over 70 years who were admitted with
acute heart failure.18 In another study in Japan, 57% of heart
failure patients between 43 and 90 years showed evidence of
sarcopenia.3 In a cohort of 200 patients with heart failure and
a mean age of 70 years, the prevalence of sarcopenia was
about 19.5%.4
In this study, we aimed to evaluate the presence of muscle
wasting in younger patients with heart failure. The result of
our study indicates that muscle wasting is relatively prevalent
in this group of patients particularly in those with lower LVEF,
higher NYHA function class, lower 6MWT distance, and
higher hospitalization rate. These findings are similar to the
results of SICA-HF study4 which shows muscle wasting is
more prevalent in heart failure patients with more critical
condition. These patients have lower LVEF and worse exer-
cise capacity in treadmill performance or 6MWT. However,
our study population were younger (<55 years old with a
mean of 37 years), and it means that as Anker et al.19 men-
tioned, the skeletal muscle is lost earlier in chronic diseases
such as heart failure, and this muscle mass loss can be accel-
erated in heart failure independent of ageing process.
In the present study, BMI was lower in patients with mus-
cle wasting compared with those without. This finding is
similar to other studies.4 It has been shown that heart failure
patients with higher BMI have better outcome in terms of
Table 3 Comparison of baseline and clinical findings between patients
with and without muscle wasting, n = 55
Characteristics
Muscle wasting
P valueYes n = 26 No n = 29
Gender, number (%)
Female 8 (30.8) 15 (51.7) 0.1
Male 18 (69.2) 14 (48.3)
Age (year), mean (SD) 36 (11.4) 38.5 (8.8) 0.3
BMI (kg/m2), mean (SD) 22.4 (2.6) 26.1 (3.8) <0.001
LVEF (%), mean (SD) 18.1 (8.2) 24.3 (9.5) 0.01
NYHA class, number (%)
I 6 (23.1) 14 (48.3) 0.01
II 14 (53.8) 14 (48.3)
III 6 (23.1) 1 (3.4)
Fatigue 15 (57.7) 11 (38) 0.1
Dizziness 4 (15.4) 1 (3.4) 0.1
Loss of appetite 13 (50) 11 (38) 0.4
Duration of illness (year),
median (IQR)
2 (1–2) 2 (2–2.5) 0.1
Admission within the past
3 months
12 (46.2) 4 (13.8) 0.008
BMI, body mass index; IQR, interquartile range; LVEF, left
ventricular ejection fraction; NYHA, New York Heart Association;
SD, standard deviation.
Table 4 Comparison of laboratory findings between patients with and
without muscle wasting, n = 55
Characteristics
Muscle wasting
P valueYes n = 26 No n = 29
NT-pro BNP (ng/dL),
median (IQR)
836 (139–2400) 833 (100–1462) 0.5
6-MWT distance
(metre)
338 (140) 440 (124.5) 0.01
Haemoglobin (g/L) 13.8 (2) 13.8 (1.9) 0.8
Serum total protein
(g/L)
71 (7.1) 69 (5.1) 0.3
Serum albumin (g/L) 43.1 (5.1) 43.2 (4.9) 0.9
BUN (mg/dL) 20.2 (6.7) 17.7 (5.8) 0.1
Creatinine (mg/dL) 0.8 (0.2) 0.9 (0.17) 0.5
Sodium (mmol/L) 136 (4.6) 138 (3.9) 0.1
Potassium (mmol/L) 4.2 (0.4) 4.2 (0.4) 0.6
Triglyceride (mg/dL) 140.5 (91.3) 167.6 (83.2) 0.4
Cholesterol (mg/dL) 156.8 (66) 191.6 (42.6) 0.1
LDL (mg/dL) 95.5 (44.7) 107.3 (28) 0.4
HDL (mg/dL) 38.1 (5.4) 42.5 (14) 0.3
Vitamin D3 level
(ng/mL)
16.1(11.7) 22.4 (18.5) 0.1
Osteopenia in BMD,
number (%)
10 (38.5) 11 (37.9) 0.9
ASM/height ratio
(kg/m2)
5993.2 (976.3) 7089 (819.7) 0.0001
6MWT, 6-min walk test; ASM, appendicular muscle mass; BMD,
bone mass densitometry; BUN, blood urea nitrogen; HDL, high
density lipoprotein; LDL, low density lipoprotein; NT-pro BNP,
N-terminal pro brain natriuretic peptide.
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mortality and hospitalization (obesity paradox),20 and the
strong association between BMI and muscle wasting in the
present study may be an explanation for this finding. A heart
failure patient with higher BMI may have a better skeletal
muscle composition as a result of less metabolic and neuro-
hormonal derangements and therefore better clinical
outcome.
For as far as we have studied and researched, only a few
studies have investigated younger heart failure patients re-
garding muscle wasting. Obata et al. reported a prevalence
of 45.5% for muscle wasting in heart failure patients aged un-
der 65 years.3 Although the prevalence of muscle wasting in
the Obata et al. study is similar to our study, considering
the lower mean of age in our study (37.3 ± 10.1), it seems
that muscle wasting would be more prevalent in Iranian
population.
Although muscle wasting is more expected with ageing, we
observed a high prevalence in our quite young population of
heart failure patients. This can be attributed to the following
factors.
The muscle wasting in the setting of heart failure is
multi-factorial. Impaired cardiac performance results neuro-
hormonal and metabolic abnormalities. The inflammatory
process secondary to heart failure leads to an imbalance
between anabolism and catabolism. The catabolic signals
directly affect skeletal muscle and lead to protein break
down and muscle mass loss. It has been shown that inflam-
matory cytokines such as interleukin-6 and tumour necro-
tizing factor-α intensify the catabolic pathways and result
in structural and functional impairment of skeletal muscles
which play an important role in pathogenesis of heart
failure and its progression.1,2,4,9,16 This imbalance between
catabolism and anabolism seems to be independent of
the LVEF because a recent study by Bekfani et al. has
shown similar prevalence of muscle wasting in patients
with heart failure-preserved ejection fraction.21 The current
study was run at a tertiary cardiovascular referral centre
specialized in care of advanced heart failure and cardiac
transplantation. Most of the young heart failure patients
were those referred from other cities to be listed for car-
diac transplantation, and a large number had to be hospi-
talized at the very first visit, apparently sick debilitated
end-stage heart failure patients in whom muscle wasting
is expected. A more severe neurohormonal and metabolic
abnormality may be the reason for development of muscle
wasting in a much earlier state.
Being physically active and exercise training can signifi-
cantly improve the skeletal muscle dysfunction in patients
with heart failure.1,15,16,22 Geilen et al. showed that exercise
training results in reduction of proteasome systems involved
in muscle proteolysis in skeletal muscle of younger and older
patients with heart failure.22 Unfortunately, regular exercise
and physical activity is not common among Iranian popula-
tion even in healthy persons, and many people in Iran are
physically deconditioned.23–25 This may be another explana-
tion for high prevalence of muscle wasting in our study pop-
ulation. The assessment of muscle mass in normal young
Iranian population would be useful for a better explanation
of this issue.
Another issue in evaluation of patients with muscle
wasting is nutritional problems. It has been shown that
malnutrition and low protein intake can be responsible for
muscle wasting in heart failure patients, particularly in those
with sedentary life style and physical inactivity.26–29 Although
the albumin and protein level were within the normal limits
in our study population, it cannot be easily concluded that
the protein turnover is not disturbed in our study
population.
Heart failure has been revisited and known as an impor-
tant entity requiring medications and devices to help and
specialized physicians and nurses to take care of heart failure
patients to live better and longer. Yet there are many old
fashioned (and sometimes incorrect) recommendations to
heart failure patients like prohibiting exercise activity,
insisting on the low-fat low-calorie diet famous for primary
prevention of coronary artery disease, insisting continuation
of medications that have been found futile in the presence
of advanced heart failure (like Statins), and not addressing
the common mood-anxiety disorders. On the other hand, it
is worthy to note that heart failure patients cannot benefit
from ‘ventricular assist device’ treatment in our country be-
cause of cost issues, and many go into severe right ventricular
failure and multi-organ involvement.
Study limitations
The careful selection of patients to reduce confounders is the
strength of the present study; however, some limitations are
present in this study:
1) Although the evaluation of muscle mass by DXA is an ap-
proved method, there are some limitations in the assess-
ment of fat free mass by this method, and other methods
such as computed tomography scanning and magnetic
resonance imaging are more precise modalities for assess-
ment of skeletal muscle mass.
2 We could find a good relationship between the 6-min walk
distance, as a surrogate for skeletal muscle function, and
muscle wasting, but it would be better if we could
measure muscle power and function by more specific
tests.
3 It would be better if we could assess exercise capacity by
ergospirometry.
4 Small sample size and lack of follow-up data are other
limitations of this study.
5 Our study is by far the first report of muscle wasting in
Iranian heart failure patients, and we believe further
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studies are needed to investigate whether factors related
to race and ethnicity play any role in higher prevalence
of muscle wasting in heart failure patients.
Conclusions
We concluded that muscle wasting might be present in
younger patients with heart failure particularly in those
who are in worse clinical condition. This is the first study
of muscle wasting in heart failure patients in Iran and could
be the basis of further evaluations and basic and clinical
trials in this issue.
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